A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00136591
Recruitment Status : Terminated (An arm closed due to lack of efficacy)
First Posted : August 29, 2005
Last Update Posted : October 26, 2010
Janssen-Cilag International NV
Information provided by:
Lymphoma Study Association